Positive correlations between serum and plasma matrix metalloproteinase (MMP)-2 or MMP-9 levels in disease conditions

Clinical Chemistry and Laboratory Medicine

Volumn 47, Issue 7, 2009, Pages 888-891

  Gerlach, Raquel F ^a   Meschiari, Cesar A ^a   Marcaccini, Andrea M ^a   Palei, Ana C T ^b   Sandrim, Valeria C ^a   Cavalli, Ricardo C ^a   Tanus Santos, Jose E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Metalloproteinases; Plasma; Serum

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; BLOOD SAMPLING; CLINICAL ARTICLE; CORRELATION ANALYSIS; DEVICE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LETTER; MATERNAL HYPERTENSION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL;

ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PLASMA; PREGNANCY; REAGENT KITS, DIAGNOSTIC; SERUM; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 67849094449     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2009.203     Document Type: Letter

References (11)

1. Souza-Costa DC, Figueiredo-Lopes L, Alves-Filho JC, Semprini MC, Gerlach RF, Cunha FQ, et al. Protective effects of atorvastatin in rat models of acute pulmonary embolism: involvement of matrix metalloproteinase-9. Crit Care Med 2007;35:239-45.
2. Palei AC, Sandrim VC, Cavalli RC, Tanus-Santos JE. Comparative assessment of matrix metalloproteinase (MMP)- 2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension. Clin Biochem 2008;41: 875-80.
3. Palei AC, Zaneti RA, Fortuna GM, Gerlach RF, Tanus-Santos JE. Hemodynamic benefits of matrix metalloprotei- nase-9 inhibition by doxycycline during experimental acute pulmonary embolism. Angiology 2005;5:611-7.
4. Demacq C, Metzger IF, Gerlach RF, Tanus-Santos JE. Inverse relationship between markers of nitric oxide formation and plasma matrix metalloproteinase-9 levels in healthy volunteers. Clin Chim Acta 2008;394:72-6.
5. Martinez ML, Castro MM, Rizzi E, Fernandes K, Demacq C, Bendhack LM, et al. Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dys-function in renovascular hypertensive rats. Eur J Pharmacol 2008;591:224-30.
6. Martinez ML, Lopes LF, Coelho EB, Nobre F, Rocha JB, Gerlach RF, et al. Lercanidipine reduces matrix metallo- proteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol 2006;47:117-22.
7. Mannello F. Serum or plasma samples? The "Cinderella" role of blood collection procedures: preanalytical methodological issues influence the release and activity of circulating matrix metalloproteinases and their tissue inhibitors, hampering diagnostic trueness and leading to misinterpretation. Arterioscler Thromb Vasc Biol 2008;28:611-4.
8. Gerlach RF, Demacq C, Jung K, Tanus-Santos JE. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem 2007;40:119-23.
9. Mannello F, Tanus-Santos JE, Meschiari CA, Tonti GA. Differences in both matrix metalloproteinase 9 concentration and zymographic profile between plasma and serum with clot activators are due to the presence of amorphous silica or silicate salts in blood collection devices. Anal Biochem 2008;374:56-63.
10. Thrailkill K, Cockrell G, Simpson P, Moreau C, Fowlkes J, Bunn RC. Physiological matrix metalloproteinase (MMP) concentrations: comparison of serum and plasma specimens. Clin Chem Lab Med 2006;44:503-4.
11. Gerlach RF, Uzuelli JA, Souza-Tarla CD, Tanus-Santos JE. Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal Biochem 2005;344:147-9.